130233-28-2Relevant academic research and scientific papers
Novel ibuprofen prodrugs with improved pharmacokinetics and non-ulcerogenic potential
Dhakane, Valmik D.,Chavan, Hemant V.,Thakare, Vishnu N.,Adsul, Laxman K.,Shringare, Sadanand N.,Bandgar, Babasaheb P.
, p. 503 - 517 (2014)
In the present study, we evaluated the anti-inflammatory activity with pharmacokinetic, ulcerogenic properties of various synthesized prodrugs of ibuprofen in experimental animals. Prodrugs 2, 6, 9, 10, 12, and 14 were found to possess significant anti-inflammatory activity with almost non-ulcerogenic potential than standard drug ibuprofen 1a in both normal and inflammation-induced rats. Metabolic stability of prodrugs 2, 6, 9, 10, 12, and 14 were also studied in rat liver microsomes and oral bioavailability was determined by estimating area under curve (AUC) and plasma concentration of these prodrugs at various time intervals. The experimental findings elicited higher AUC and plasma concentration at 1 and 2 h indicating improved oral bioavailability as compared to parent ibuprofen. These prodrugs are found to have least gastric ulceration with retain anti-inflammatory activity observed in experimental animals. Therefore, present experimental findings demonstrated significant improvement of various pharmacokinetic properties with least ulcerogenic potential of ester prodrugs of ibuprofen an anti-inflammatory agent
Antibacterial agents containing oxo-4-pyridine carboxylic acid derivatives
-
, (2012/06/05)
The present invention relates to novel antibacterial agents, corresponding to the following general formula I STR1 in which: Q represents an aromatic ring, X represents a hydrogen atom or a linear or branched alkyl group, Y represents a linkage or an alkyl group, Z represents a hydrogen atom, an alkyl, aralkyl or heteroalkyl group. These compounds constitute anti-bacterial agents with multiple pharmacological activity.
